Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Renal, and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NEDD4L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NEDD4L Recombinant Protein (WT & C942S Catalytic Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for in vitro ubiquitination assays. |
View NEDD4L Products |
| Gene Delivery | NEDD4L Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View NEDD4L Products |
| Benchmark Ab | Anti-NEDD4L Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IP validation. |
View NEDD4L Products |
| Validator | NEDD4L siRNA Set For knockdown verification and target specificity validation. |
View NEDD4L Products |
| Related Target A | SCNN1A (ENaC alpha subunit) Primary physiological substrate of NEDD4L; critical for hypertension and Liddle syndrome research. |
View SCNN1A Products |
| Related Target B | SMAD3 Downstream mediator of TGF-beta signaling regulated by NEDD4L ubiquitination; key in fibrosis and oncology. |
View SMAD3 Products |
| Related Target C | NEDD4 Closest homolog of NEDD4L; essential counter-screening target to ensure drug selectivity. |
View NEDD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro E3 Ligase Activity Validation | High-purity active recombinant NEDD4L proteins and catalytic inactive mutants (C942S) sequence-verified by LC-MS. |
| Homolog Selectivity Screening (NEDD4L vs. NEDD4) | Matched active protein panels for both NEDD4L and NEDD4 to perform parallel selectivity assays. |
| Lack of Reliable Screening Assays | Sequence-verified WW domain fragments available for peptide-binding interaction assays. |
| Off-Target Assessment in Cell Models | Pre-validated siRNA sets and Lentivirus particles for robust knockdown and overexpression controls. |
Live NEDD4L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NEDD4L therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum ubiquitin proteasome system (UPS) modulators to target-specific small molecule allosteric regulators and PROTAC linkers. As first-generation E3 ligase therapies reach the clinic, the next wave of R&D is targeting NEDD4L for its pivotal role in regulating epithelial sodium channels (ENaC) and the TGF-beta/Smad pathway. This makes it a highly attractive target for hypertension, chronic kidney disease (CKD), pulmonary fibrosis, and specific oncology indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Hypertension, Respiratory Distress | E3 ligase assay validation (Need sequence-verified active proteins) |
| PROTAC / Molecular Glues | Targeted Protein Degradation (TPD) Pioneers | Oncology, Fibrotic Diseases | Ternary complex formation assays (Need high-purity WW domain proteins) |
| Gene Therapy / RNAi | RNA Therapeutics Developers | Liddle Syndrome, Kidney Diseases | In vitro validation (Need validated siRNA and Lentiviral systems) |